🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Enfortumab Vedotin now approved U.S. FDA for post PD1 setting! - regardless of prior platinum- in pts with metastatic UC, cis- ineligible 👏🏻based on EV201-c2 +301 Arjun Balar MD Daniel Petrylak Bradley McGregor Jonathan Rosenberg MD Andrea Necchi Michael Harrison Tian Zhang, MD, MHS Dan George

1/ On the heels of ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab in mRCC just published in NEJM ! A step towards better outcomes for all our patients with kidney cancer! nejm.org/doi/full/10.10… OncoAlert Tom Powles

RII PRISM study tests 3 monthly IPI vs standard IPI (3 weekly) as part of IPI/NIVO in mRCC (n=293). The modified regimen had less grade 3/4 toxicity but had similar RR and PFS. OS is immature but also looks similar. Delaying IPI seems safe for those struggling with tox. #ESMO21

A spectacular practice changing benifit for adding abiraterone to RT and ADT for high risk M0 Prostate cancer . 40% !!! Reduction in the risk of death. Congrats to the team

Claim your section 3 credits #OnDemand Advanced Renal Cell Carcinoma (aRCC) Script Concordance Test Learning Program #UROpediaCanada Aly-Khan Lalani Dominick Bossé, MD MPH

It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021: Some negative, some positive, some led to FDA Oncology approval; we learned from all! Feel free to add & retweet & tag anyone involved This is not an exhaustive list OncoAlert

8/ Phase 3 EV-301 trial showing improved PFS and OS with EV (vs. chemo) in patients with previously treated mUC Tom Powles Barts Cancer Centre Jonathan Rosenberg MD @sloan_kettering Daniel Petrylak Yale Cancer Center Daniel Castellano Yohann Loriot Guru P. Sonpavde, MD Dana-Farber Lank Center for Genitourinary Oncology nejm.org/doi/full/10.10…

Grateful to The Lancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) thelancet.com/journals/lance…

#CKCF22: Gloves are off for fun and informative debate on adjuvant IO in #RCC - captures contemporary talking points in this evolving space! Yay Rana McKay, MD, FASCO Nay Anil Kapoor, MD, FRCSC Canadian Urological Association Simon Tanguay Jeffrey Graham @Merregan @lukelavallee

1 Meeting #CKCF2022 4 teams...some injuries later! We have a winning team w/ @lukelavallee Kristen McAlpine Rod Breau . Thank you participants! Are we having bingo next year Anil Kapoor, MD, FRCSC ? Aly-Khan Lalani Shaan Dudani Bimal Bhindi Dominick Bossé, MD MPH Tiffany Pizioli Simon Tanguay Naveen Basappa, MD

Amazing podcast! Please read about the genesis of IMDC and our efforts with Daniel Heng with Wanling @Merregan and many #IMDC such as Laurence Albiges Rana McKay, MD, FASCO Aly-Khan Lalani Dominick Bossé, MD MPH Chris Labaki Ziad Bakouny, MD, MSc Dana-Farber Lank Center for Genitourinary Oncology and many Tom Baker Cancer Center !

Hot off the press! Check out the latest CKCF Consensus Statement; "Adjuvant therapy for RCC: 2023." cuaj.ca/index.php/jour… Aly-Khan Lalani @lukelavallee Naveen Basappa, MD Rod Breau Bimal Bhindi Simon Tanguay Neil Reaume MD Jeffrey Graham Dominick Bossé, MD MPH Shaan Dudani Daniel Heng

Neoadjuvant atezo in non-urothelial cancer subtypes led by Bernadett Szabados Barts Experimental Cancer Medicine Centre #ESMO23 . Firstly, the inconsistency in pathology review is problematic. Secondly, the responders in the sarcomatoid group was very high - as in renal cancer. These patients need IO at some point.

⭐️Dr. Daniel Heng gives an outstanding discussion on the road ahead in renal cell cancer. #OncLiveTakeOver 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 #ESMO23 Daniel Heng Sumanta K. Pal, MD, FASCO Toni Choueiri, MD

🚨Please do not miss one of the most awaited Presidential sessions with 2 practice-changing studies in UC! 📍Madrid auditorium 🕗 4:30pm 👥 Tom Powles Michiel van der Heijden Andres Cervantes silke gillessen #ESMO23 ESMO - Eur. Oncology OncoAlert

Simply "presidential"! Tom Powles presents the first combinations thats beats chemotherapy in 1L mUC for survival!! At 17.2mo f/up PFS HR=0.45, OS HR=0.47 Congrats to the investigators, scientific community and patients! #ESMO23 ESMO - Eur. Oncology OncoAlert

Amazing to watch history being made (virtually at the moment) by Tom Powles @bartsemc. Huge congrats to the #EV302 investigators. Love Tom's comment re: the many pts who participated not just in this study but in the many preceding studies who helped us get to this point.

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

With the many advances in treatment options for #kidneycancer shared decision-making has never been more important. Dominick Bossé, MD MPH was the lead physician in developing a systemic therapy decision guide which he will present at our Forum. Registration: bit.ly/KCCforum2023

Hey Air Canada - I took a flight recently and left on time. Then I woke up and headed to the airport. 🙄